Document:

Form of Indemnification Agreement between the Registrant and its officers

 Exhibit 10.5 
 FORM OF INDEMNIFICATION AGREEMENT 
 AGREEMENT made as of this     
day of                      2006, between Endoceutics, Inc., a Quebec corporation (the “Company”), and
                    , an individual (the “Indemnitee”} 
 WHEREAS, it is essential to the Company and its stockholders to attract and retain qualified and capable [management]; 
 WHEREAS, in recognition of Indemnitee’s need for protection against personal liability and in order to induce Indemnitee to serve the Company in an
effective manner, and to supplement or replace the Company’s directors’ and officers’ liability insurance coverage, and, in part, to provide Indemnitee with specific contractual assurance that indemnification protection will be
available to the Company wishes to provide the Indemnitee with the benefits contemplated by this Agreement; and 
 WHEREAS, as a result of
the provision of such benefits Indemnitee has agreed to serve the Company as a [officer] [director]; 
 NOW, THEREFORE,
the parties hereto hereby agree as follows: 
 1. Definitions. The following terms, as used herein, shall have the following respective
meanings: 
 a. Affiliate: of a specified Person is a Person who directly, or indirectly through one or more intermediaries,
controls or is controlled by, or is under common control with, the Person specified. The term Associate used to indicate a relationship with any Person shall mean (i) any corporation or organization (other than the Company or a Subsidiary) of
which such Person is an officer or partner or is, directly or indirectly, the Beneficial Owner of ten (10) percent or more of any class of Equity Securities; (ii) any trust or other estate in which such Person has a substantial beneficial
interest or as to which such Person serves as trustee or in a similar fiduciary capacity (other than an Employee Plan Trustee), (iii) any Relative of such 
 b. Beneficial Ownership: shall be determined, and a Person shall be the Beneficial Owner of all securities which such Person is deemed to own beneficially, pursuant to Rule 13d-3 of the General Rules and
Regulations under the Securities Exchange Act of 1934, as amended (or any successor rule or statutory provision), or, if such Rule 13d-3 shall be rescinded and there shall be no successor rule or statutory provision thereto, pursuant to such Rule
13d-3 as in effect on the date hereof; provided, however, that a Person shall, in any event, also be deemed to be the Beneficial Owner of any Voting Shares: (A) of which such Person or any of its Affiliates or Associates is, directly or
indirectly, the Beneficial Owner; or (B) of which such Person or any of its Affiliates or Associates has (i) the right to acquire (whether such right is exercisable immediately or only after the passage of time), pursuant to any agreement,
arrangement or understanding or upon the exercise of conversion rights, exchange rights, warrants or options, or otherwise, and (ii) sole or shared voting or investment power with respect 

 thereto pursuant to any agreement, arrangement, understanding, relationship or otherwise (but shall not be deemed to be
the Beneficial Owner of any Voting Shares solely by reason of a revocable proxy granted for a particular meeting of stockholders, pursuant to a public solicitation of proxies for such meeting, with respect to shares of which neither such Person nor
any such Affiliate or Associate is otherwise deemed the Beneficial Owner), or (C) of which another Person is, directly or indirectly, the Beneficial Owner if such first mentioned Person or any of its Affiliates or Associates acts with such
other Person as a partnership, syndicate or other group pursuant to any agreement, arrangement or understanding for the purpose of acquiring, holding, voting or disposing of any shares of capital stock of the Company; and provided
further, however, that (i) no director or officer of the Company, nor any Associate or Affiliate of any such director or officer, shall, solely by reason of any or all of such directors and officers acting in their capacities as
such, be deemed for any purpose hereof, to be the Beneficial Owner of any Voting Shares of which any other such director or officer (or any Associate or Affiliate thereto) is the Beneficial Owner (ii) no trustee of an employee stock ownership
or similar plan of the Company or any Subsidiary (“Employee Plan Trustee”) or any Associate or Affiliate of any such Trustee, shall, solely by reason of being an Employee Plan Trustee or Associate or Affiliate of an Employee Plan Trustee,
be deemed for any purposes hereof to be the Beneficial Owner of any Voting Shares held by or under any such plan. 
 [OPTIONAL] (c) A
Change in Control: shall be deemed to have occurred if (A) any Person (other than (a) the Company or any subsidiary, or (b) any pension, profit sharing, employee stock ownership or other employee benefit plan of the
Company or any subsidiary or any trustee of or fiduciary with respect to any such plan when acting in such capacity) is or becomes, after the date of this Agreement, the Beneficial Owners of [    %] or more of the total voting
power of the Voting Shares, (B) during any period of two consecutive years, individuals who at the beginning of such period constitute the Board of Directors of the Company and any new director whose election or appointment by the Board of
Directors or nomination or recommendation for election by the Company’s stockholders was approved by a vote of at least two-thirds (2/3) of the directors then still in office who either were directors at the beginning of the period or
whose election or nomination for election was previously so approved, cease for any reason to constitute a majority thereof, or (C) the stockholders of the Company approve a merger or consolidation of the Company with any other corporation,
other than a merger or consolidation which would result in the Voting Shares of the Company outstanding immediately prior thereto continuing to represent (either by remaining outstanding or by being converted into Voting Shares of the surviving
entity) at least 75 % of the total voting power represented by the Voting Shares of the Company or such surviving entity outstanding, or the stockholders of the Company approve a plan of complete liquidation of the Company or an
agreement for the sale or disposition by the Company of all or substantially all of the Company’s assets. 
  

 -2- 

 (d) Claim: means any threatened, pending or completed action, suit, arbitration or
proceeding, or any inquiry or investigation, whether brought by or in the right of the Company or otherwise, that Indemnitee in good faith reasonably believes might lead to the institution of any such action, suit, arbitration or proceeding, whether
civil, criminal, administrative, investigative or other, or any appeal therefrom. 
 (e) Equity Security: shall have the
meaning given to such term under Rule 3a1 1-1 of the General Rules and Regulations under the Securities Exchange Act of 1934, as in effect on the date hereof. 
 (f) D&O Insurance: means any valid directors’ and officers’ liability insurance policy maintained by the Company for the benefit of the Indemnitee, if any. 
 (g) Determination: means a determination, and Determined means a matter which has been determined based on the facts known at
the time, by: (i) a majority vote of a quorum of disinterested directors, or (ii) if such a quorum is not obtainable, or even if obtainable, if a quorum of disinterested directors so directs, by independent legal counsel in a written
opinion, or, in the event there has been a Change in Control, by the Special Independent Counsel (in a written opinion) selected by Indemnitee as set forth in Section 6, or (iii) a majority of the disinterested stockholders of the Company,
or (iv) a final adjudication by a court of competent jurisdiction. 
 (h) Excluded Claim: means any payment for
Losses or Expenses in connection with any Claim: (i) based or attributable to Indemnitee personally gaining in fact any financial profit or other advantage to which Indemnitee is not legally entitled; or (ii) for the return by Indemnitee
of any remuneration paid to Indemnitee without the previous approval of the stockholders of the Company which is illegal; or (iii) for an accounting of profits in fact made from the purchase or sale by Indemnitee of securities of the Company
within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or similar provisions of any state law; or (iv) resulting from Indemnitee’s knowingly fraudulent, dishonest or willful misconduct; or
(v) resulting from the Indemnitee’s bad faith or as a result of active and deliberate dishonesty which was material to the adjudicated cause of action or (vi) the payment of which by the Company under this Agreement is not permitted
by applicable law. 
 (i) Expenses: means any reasonable expenses incurred by Indemnitee as a result of a Claim or Claims made
against Indemnitee for Indemnifiable Events including, without limitation, reasonable attorneys’ fees and all other costs, expenses and obligations paid or incurred in connection with investigating, defending, being a witness in or
participating in (including on appeal), or preparing to defend, be a witness in or participate in any Claim relating to any Indemnifiable Event. 
 (j) Fines: means any fine, penalty or, with respect to an employee benefit plan, any excise tax or penalty assessed with respect thereto. 
  

 -3- 

 (k) Indemnifiable Event: means any event or occurrence, occurring prior to or after the
date of this Agreement, related to the fact that Indemnitee is, was or has agreed to serve as, a director, officer, employee, consultant, trustee, agent or fiduciary of the Company, or is or was serving at the request of the Company as a director,
officer, employee, consultant trustee, agent or fiduciary of another corporation, partnership, joint venture, employee benefit plan, trust or other enterprise, or by reason of anything done or not done by Indemnitee, including, but not limited to,
any breach of duty, neglect, error, misstatement, misleading statement, omission, or other act done or wrongfully attempted by Indemnitee, or any of the foregoing alleged by any claimant, in any such capacity. 
 (1) Losses: means any amounts or sums which Indemnitee is legally obligated to pay as a result of a Claim or Claims made against Indemnitee
for Indemnifiable Events including, without limitation, damages, judgments and sums or amounts paid in settlement of a Claim or Claims, and Fines. 
 (m) Person: means any individual, partnership, corporation, limited liability company, business trust, joint stock company, trust, unincorporated association, joint venture, governmental authority or other entity of whatever
nature. 
 (n) Potential Change in Control: shall be deemed to have occurred if (A) the Company, enters into an agreement,
the consummation of which would result in the occurrence of a Change in Control; or (B) the Board of Directors adopts a resolution to the effect that, for purposes of this Agreement, a Potential Change in Control has occurred. 
 (o) Relative: means a Person’s spouse, parents, children, siblings, mother- and father-in-law, sons- and daughters-in-law, and
brothers- and sisters-in-law. 
 (p) Reviewing Party: means any appropriate person or body consisting of a member or members of
the Company’s Board of Directors or any other person or body appointed by the Board (including the Special Independent Counsel referred to in Section 6) who is not a party to the particular Claim for which Indemnitee is seeking
indemnification. 
 (q) Subsidiary: means any corporation of which a majority of any class of Equity Security is owned,
directly or indirectly, by the Company. 
 (r) Trust: means the trust established pursuant to Section 7 hereof.

 (s) Voting Shares: means any issued and outstanding shares of capital stock of the Company entitled to vote generally in the
election of directors. 
 2. Basic Indemnification Agreement. In consideration of, and as an inducement to, the Indemnitee rendering
valuable services to the Company, the Company agrees that in the event Indemnitee is or becomes a party to or witness or other participant in, or is threatened to be made a party to or witness or other participant in, a Claim by reason of (or
arising in part out of) an Indemnifiable Event, the Company will indemnify Indemnitee to the 
  

 -4- 

 fullest extent authorized by law, against any and all Losses and Expenses (including all interest, assessments and other
charges paid or payable in connection with or in respect of such Losses and Expenses) of such Claim, whether or not such Claim proceeds to judgment or is settled or otherwise is brought to a final disposition, subject in each case, to the further
provisions of this Agreement. 
 3. Limitations on Indemnification. Notwithstanding the provisions of Section 2, Indemnitee shall not
be indemnified and held harmless from any Losses or Expenses (a) which have been Determined, as provided herein, to constitute an Excluded Claim; (b) indemnifiable hereunder if and to the extent that Indemnitee has actually received
payment in connection with such Losses and Expenses pursuant to the Certificate of Incorporation, By-laws, D&O Insurance or otherwise; or (c) other than pursuant to the last sentence of Section 4(d) or Section 14, in connection
with any claim or proceeding initiated by Indemnitee, or brought or made by Indemnitee against the Company or any director or officer of the Company, unless the Company has joined in or the Board of Directors has authorized such claim or proceeding.

 4. Indemnification Procedures. 
 (a) Promptly after receipt by Indemnitee of notice of any Claim, Indemnitee shall, if indemnification with respect thereto may be sought from the Company under this Agreement, notify the Company of the commencement thereof; provided,
however, that the failure to give such notice promptly shall not affect or limit the Company’s obligations with respect to the matters described in the notice of such Claim, except to the extent that the Company is prejudiced thereby.
Indemnitee agrees, further, not to make any admission or effect any settlement with respect to such Claim without the consent of the Company, except any Claim with respect to which the Indemnitee has undertaken the defense in accordance with the
second to last sentence of Section 4(d). 
 (b) If, at the time of the receipt of such notice, the Company has D&O Insurance in
effect, the Company shall give prompt notice of the commencement of any Claim to the insurers in accordance with the procedures set forth in the respective policies. The Company shall thereafter take all necessary or desirable action to cause such
insurers to pay, on behalf of Indemnitee, all Losses and Expenses payable as a result of such Claim. 
 (c) The Indemnitee shall be entitled
employ counsel of its choosing in defense of all Claims, and the Company shall be liable to Indemnitee under this Agreement for any legal or other Expenses incurred by Indemnitee in connection with such defense. The Company shall be obligate to pay
the Expenses of any Claim in advance of the final disposition thereof. 
 (d) All payments on account of the Company’s indemnification
obligations under this Agreement shall be made within five (5) days of Indemnitee’s written request therefor unless a Determination is made that the Claims giving rise to Indemnitee’s request are Excluded Claims or otherwise not
payable under this Agreement, and all payments on account of the Company’s obligation to pay Expenses under Section 4(c) of this Agreement prior to the final 
  

 -5- 

 disposition of any Claim shall be made within five (5) days of Indemnitee’s written request therefor and such
obligation shall not be subject to any such Determination but shall be subject to Section 4(e) of this Agreement. Notwithstanding the foregoing, such five (5) day period may be extended for a reasonable time, not to exceed an additional
fifteen (15) days, if the Person making the Determination with respect to entitlement to indemnification in good faith requires such additional time for the obtaining or evaluating of documentation and/or information relating thereto. In the
event the Company takes the position that Indemnitee is not entitled to indemnification in connection with the proposed settlement of any Claim, Indemnitee shall have the right at his own expense to undertake defense of any such Claim, insofar as
such proceeding involves Claims against the Indemnitee, by written notice given to the Company within 10 days after the Company has notified Indemnitee in writing of its contention that Indemnitee is not entitled to indemnification; provided,
however, that the failure to give such notice within such 10-day period shall not affect or limit the Company’s obligations with respect to any such Claim if such Claim is subsequently determined not to be an Excluded Claim or otherwise to be
payable under this Agreement, except to the extent that the Company is prejudiced thereby. If it is subsequently determined in connection with such proceeding that the Indemnifiable Events are not Excluded Claims and that Indemnitee, therefore, is
entitled to be indemnified under the provisions of Section 2 hereof, the Company shall promptly indemnify Indemnitee. 
 (e) Indemnitee
hereby expressly undertakes and agrees to reimburse the Company for all Losses and Expenses paid by the Company in connection with any Claim against Indemnitee in the event and only to the extent that a Determination shall have been made by a court
of competent jurisdiction in a decision from which there is no further right to appeal that Indemnitee is not entitled to be indemnified by the Company for such Losses and Expenses because the Claim is an Excluded Claim or because Indemnitee is
otherwise not entitled to payment under this Agreement. 
 (f) In connection with any Determination as to whether Indemnitee is entitled to
be indemnified hereunder, the burden of proof shall be on the Company to establish that Indemnitee is not so entitled. 
 (g) Indemnitee
hereby expressly undertakes and agrees to (i) notify (and deliver to, as applicable) the Company in writing of any and all information or documents relating to any Claim or matter which may entitle Indemnitee to indemnification for Losses or
Expenses under this Agreement; and (ii) to notify the Company in writing of any and all developments relating to any Claim to which the Company has notified Indemnitee in writing pursuant to the terms of Section 4(d) herein of its
contention that Indemnitee is not entitled to indemnification under this Agreement. 
 5. Settlement. The Company shall have no
obligation to indemnify Indemnitee under this Agreement for any amounts paid in settlement of any Claim effected without the Company’s prior written consent. The Company shall not settle any Claim in which it takes the position that Indemnitee
is not entitled to indemnification in connection with such settlement without the consent of Indemnitee, nor shall the Company settle any Claim in any 
  

 -6- 

 manner which would impose any Fine or any obligation on Indemnitee, without Indemnitee’s written consent. Neither
the Company nor Indemnitee shall unreasonably withhold its or his consent to any proposed settlement. 
 [OPTIONAL] 6. Change in Control:
Extraordinary Transactions. The Company and Indemnitee agree that if there is a Change in Control of the Company (other than a Change in Control which has been approved by a majority of the Company’s Board of Directors who were directors
immediately prior to such Change in Control), then all Determinations thereafter with respect to the rights of Indemnitee to be paid Losses and Expenses under this Agreement shall be made only by a special independent counsel (the “Special
Independent Counsel “) selected by Indemnitee and approved by the Company (which approval shall not be unreasonably withheld) or by a court of competent jurisdiction. The Company shall pay the reasonable fees of such Special Independent
Counsel and shall indemnify such Special Independent Counsel against any and all reasonable expenses (including reasonable attorneys’ fees), claims, liabilities and damages arising out of or relating to this Agreement or its engagement pursuant
hereto. 
 The Company covenants and agrees that, in the event of a Change in Control of the type described in clause (C) of
Section 1(c), the Company will use its best efforts (a) to have the obligations of the Company under this Agreement including, but not limited to, those under Section 7, expressly assumed by the surviving, purchasing or succeeding
entity, or (b) otherwise adequately to provide for the satisfaction of the Company’s obligations under this Agreement, in a manner reasonably acceptable to the Indemnitee. 
 [OPTIONAL] 7. Establishment of Trust. In the event of a Potential Change in Control, the Company shall, upon written request by Indemnitee, create
a trust (the “Trust”) for the benefit of Indemnitee and from time to time upon written request of Indemnitee shall fund the Trust in an amount sufficient to satisfy any and all Losses and Expenses which are actually paid or which
Indemnitee reasonably determines from time to time may be payable by the Company under this Agreement. The amount or amounts to be deposited in the Trust pursuant to the foregoing funding obligation shall be determined by the Reviewing Party, in any
case in which the Special Independent Counsel is involved. The terms of the Trust shall provide that upon a Change in Control: (i) the Trust shall not be revoked or the principal thereof invaded without the written consent of Indemnitee;
(ii) the trustee of the Trust shall advance, within 20 days of a request by Indemnitee, any and all Expenses to Indemnitee (and Indemnitee hereby agrees to reimburse the Trust under the circumstances under which Indemnitee would be required to
reimburse the Company under Section 4(e) of this Agreement); (iii) the Company shall continue to fund the Trust from time to time in accordance with the funding obligations set forth above; (iv) the trustee of the Trust shall promptly
pay to Indemnitee all Losses and Expenses for which Indemnitee shall be entitled to indemnification pursuant to this Agreement; and (v) all unexpended funds in the Trust shall revert to the Company upon a final determination by a court of
competent jurisdiction in a final decision from which there is no further right of appeal that 
  

 -7- 

 Indemnitee has been fully indemnified under the terms of this Agreement. The trustee of the Trust shall be chosen by
Indemnitee and shall be approved by the Company, which approval shall not be unreasonably withheld. 
 8. No Presumption. For purposes
of this Agreement, the termination of any Claim by judgment, order, settlement (whether with or without court approval) or conviction, or upon a plea of no contendere, or its equivalent, shall not, of itself, create a presumption that
Indemnitee did not meet any particular standard of conduct or have any particular belief or that a court has determined that indemnification is not permitted by applicable law. 
 9. Non-exclusivity, Etc. The rights of Indemnitee hereunder shall be in addition to any other rights Indemnitee may have under the Certificate of
Incorporation, the By-laws, the Canada Business Corporations Act, any vote of stockholders or disinterested directors or otherwise, both as to action in Indemnitee’ s official capacity and as to action in any other capacity by holding such
office, and shall continue after Indemnitee ceases to serve the Company as a director officer, employee, or consultant for so long as Indemnitee shall be subject to any Claim by reason of (or arising in part out of) an Indemnifiable Event. To the
extent that a change in the Canada Business Corporations Act (whether by statute or judicial decision) permits greater indemnification by agreement than would be afforded currently under the Certificate of Incorporation, the By-laws and this
Agreement, it is the intent of the parties hereto that Indemnitee shall enjoy by this Agreement the greater benefits so afforded by such change. 
 10. Liability Insurance. The Company shall maintain an insurance policy or policies providing directors’ and officers’ liability insurance, and the Indemnitee shall be covered by such policy or policies, in accordance with
its or their terms, in the minimum amount of $                     million. If the Company fails to maintain such insurance, or if the Company does
not maintain such policy or policies in the minimum amount of $                     million, the Indemnitee may obtain such insurance for its
or his account, and the Company shall reimburse the Indemnitee for any and all costs and expenses incurred in connection therewith. 
 11.
Subrogation. In the event of payment under this Agreement, the Company shall be subrogated to the extent of such payment to all of the rights of recovery of Indemnitee who shall execute all papers required and shall do everything that may be
necessary to secure such rights, including the execution of such documents necessary to enable the Company effectively to bring suit to enforce such rights. 
 12. Partial Indemnity, Etc. If Indemnitee is entitled under any provision of this Agreement to indemnification by the Company for some or a portion of the Losses and Expenses of a Claim but not, however, for
all of the total amount thereof, the Company shall nevertheless indemnify Indemnitee for the portion thereof to which Indemnitee is entitled. Moreover, notwithstanding any other provision of this Agreement, to the extent that Indemnitee has been
successful on the merits or otherwise in defense of any or all Claims relating in whole or in part to any Indemnifiable Event or in defense of any issue or matter therein, including dismissal without prejudice, Indemnitee shall be indemnified
against all Expenses incurred in connection thereto. 
  

 -8- 

 13. Liability of Company. Indemnitee agrees that neither the stockholders nor the directors nor
any officer, employee, consultant, representative or agent of the Company shall be personally liable for the satisfaction of the Company’s obligations under this Agreement and Indemnitee shall look solely to the assets of the Company for
satisfaction of any claims hereunder. 
 14. Enforcement. 
 (a) Indemnitee’ s right to indemnification and other rights under this Agreement shall be enforceable notwithstanding any adverse Determination by
the Company’s Board of Directors, independent legal counsel, the Special Independent Counsel or the Company’s stockholders and no such Determination shall create a presumption that Indemnitee is not entitled to be indemnified hereunder. In
any such action the Company shall have the burden of proving that indemnification is not required under this Agreement. 
 (b) In the event
that any action is instituted by Indemnitee under this Agreement, or to enforce or interpret any of the terms of this Agreement, Indemnitee shall be entitled to be paid all court costs and reasonable expenses, including reasonable counsel fees,
incurred by Indemnitee with respect to such action, unless the court determines that each of the material assertions made by Indemnitee as a basis for such action was not made in good faith or was frivolous. 
 15. Term. This Indemnification Agreement shall survive termination of the [employment agreement] of even date herewith between Indemnitee and the
Company for a period of six (6) years after such termination. 
 16. Severability. In the event that any provision of this
Agreement is determined by a court to require the Company to do or to fail to do an act which is in violation of applicable law, such provision (including any provision within a single section, paragraph or sentence) shall be limited or modified in
its application to the minimum extent necessary to avoid a violation of law, and, as so limited or modified, such provision and the balance of this Agreement shall be enforceable in accordance with their terms to the fullest extent permitted by law.

 17. Governing Law. This Agreement shall be governed by and construed in accordance with the laws of the [Province of Quebec]
applicable to agreements made and to be performed entirely within such Province. 
 18. Notices. All notices or other communications
required or permitted hereunder shall be sufficiently given for all purposes if in writing and personally delivered or sent by registered or certified mail, return receipt requested, with postage prepaid addressed as follows, or to such other
address as the parties shall have given notice of pursuant hereto: 
  

 -9- 

	 	(a)	If to the Company, to: 

  

	 	    	Endoceutics, Inc. 

	 	    	2989, rue de la Promenade 

	 	    	Quebec G1 W2 J5 

	 	    	Attn: 

  

	 	    	With a copy to: 

  

	 	(b)	If to Indemnitee, to: 

  

	 	    	With a copy to: 

 19. Counterparts. This Agreement
may be signed in counterparts, each of which and all of which, when taken together, shall constitute one and the same one and the same instrument. 
 20. Successors and Assigns. This Agreement shall be (i) binding upon all successors and assigns of the Company, including any direct or indirect successor by purchase, merger, consolidation or otherwise to all or substantially
all of the business and/or assets of the Company, and (ii) binding upon and inure to the benefit of any successors and assigns, heirs, and personal or legal representatives of Indemnitee. 
 21. Amendment; Waiver. No amendment, modification, termination or cancellation of this Agreement shall be effective unless made in a writing
signed by each of the parties hereto. No waiver of any of the provisions of this Agreement shall be deemed or shall constitute a waiver of any other provision hereof (whether or not similar) nor shall such waiver constitute a continuing waiver.

  

 -10- 

 IN WITNESS WHEREOF, the Company and Indemnitee have executed this Agreement as of the day and year first
above written 
  

			
	ENDOCEUTICS, INC.
		
	By:	 	  

	Name:	 	
	Title:	 	

 ATTEST: 
  

			
	By:	 	  

	Name:	 	
	Title:	 	

  

 -11-Agreement between EndoResearch Inc. and Schering Corporation

 Exhibit 10.7 
 AGREEMENT 
 THIS AGREEMENT, effective as of the lst day of January, 1992, between ENDORECHERCHE INC. (hereafter “ENDORECHERCHE”) a Province of Quebec, Canada
corporation and SCHERING CORPORATION, a corporation of the State of New Jersey, U.S.A., (hereafter “SCHERING”) 
 WITNESSETH:

 WHEREAS SCHERING desires to receive, and ENDORECHERCHE is willing to grant exclusive worldwide licenses under ENDORECHERCHE’s
existing and future intellectual property rights with respect to certain existing antiestrogen and antiandrogen compounds and additional compounds discovered by or on behalf of ENDORECHERCHE in the field of human and animal health during the period
of time specified in this Agreement; 
 NOW, THEREFORE, in consideration of the premises and the mutual covenants and conditions hereinafter
set forth, the parties agree as follows: 
 ARTICLE 1 – DEFINITIONS 
 As used in this Agreement, the following terms have the following meanings and the singular shall include the plural and vice versa: 
 (a) “Affiliate” means any company or organization controlling, controlled by, or under common control with SCHERING or ENDORECHERCHE, as the
case may be. For this purpose, the terms control, controlled and controlling mean ownership directly or indirectly of at least fifty percent (50%) of the stock entitled to vote, and for non-stock organizations, the right to receive at least
fifty percent (50%) of the profits. 

 (b) (1) “Earned Royalty” means the following percentages of Net Sales of each Licensed
Product, including Net Sales of Licensed Combinations thereof calculated in accordance with Paragraph (b) (2) below: 
 (A) [***]% of Net Sales up to and including U.S. $[***]. 
 (B) [***]% of net sales in excess of
U.S. $[***]. 
 (C) [***] of the royalty rates described in (A) and (B) above will be applied with
respect to Net Sales in any country in the Territory where sales of Licensed Product are not covered by a Valid Claim during the period that a product containing, as an active ingredient, compound identical to a Licensed Compound is being sold in
such country. 
 (2) With respect to Licensed Combinations, “Earned Royalty” means the foregoing percentages of the sums calculated
by multiplying Net Sales of Licensed Combinations by a fraction whose numerator is the cost of Licensed Compounds contained therein and whose denominator is the sum of the numerator and the cost (calculated on the same basis if manufactured;
otherwise on the basis of purchase price) of all other active ingredients contained therein. In each case cost is to be determined in accordance with SCHERING’s standard accounting procedures. 
  

 -2- 
 [***] Represents information redacted and filed separately with the Commission pursuant to a request for confidential treatment under Rule 406 of the Securities Act of 1933, as amended. 

 (c) “FDA” means the United States Food and Drug Administration. 
 (d) “Field” means the therapeutic and/or prophylactic use of any Licensed Compound or Licensed Product for the treatment of any disease or
condition in humans and/or animals. 
 (e) “IND” means an investigational new drug application filed with the FDA in accordance
with its rules and regulations. 
 (f) “Know-How” means all data, instructions, processes, formulae, expert opinion and information
relating to the development, manufacture, use or sale of Licensed Compounds, intermediates thereof, and Licensed Products including, without limitation, all biological, chemical, pharmacological, toxicological, pharmaceutical, physical and
analytical, clinical, safety, manufacturing and quality control data and information. 
 (g) “Licensed Combinations” means
any Licensed Products which contain, in addition to one or more Licensed Compounds, one or more other active ingredients having independent therapeutic or prophylactic effect. 
 (h) “Licensed Compounds” means (i) any compounds existing on the effective date of this Agreement which were conceived of as antiestrogen
or antiandrogen compounds by or on behalf of ENDORECHERCHE and (ii) any additional novel or existing compounds which are conceived of as compounds in the Field by or on behalf of ENDORECHERCHE while carrying out research in the program as

  

 -3- 

 
that term is defined in Paragraph (a) of Article 4 of this Agreement during the [***] year period commencing on the effective date of this
Agreement, as such period may be extended. 
 (i) “Licensed products” means any pharmaceutical products in dosage form which
contain one or more Licensed Compounds, including without limitation, Licensed Combinations. 
 (j) “NDA” means a new drug
application filed with the FDA in accordance with its rules and regulations. 
 (k) “Net Sales” means the gross amounts received
from sales of Licensed Products by SCHERING, its Affiliates or sublicensees to third party customers after deduction of [(1) cash, trade and/or quantity discounts; (2) amounts repaid or credited by reason of rejections or returns of goods,
rebates or because of retroactive price reductions; and (3) freight, postage, and duties paid for. 
 (1) “Patent Rights”
means (i) all pending United States patent applications and issued patents relating to Licensed Compounds described in Paragraph (h)(i) of Article 1, including without limitation, the pending United States patent applications and issued patents
listed, as of the effective date of this Agreement, in Exhibit A attached hereto and made a part hereof; (ii) all claims of any patent applications or issued patents filed or issued during or after the term of this Agreement to which Fernand Labrie,
M.D. and/or ENDORECHERCHE have rights covering any compositions for, processes for or methods of use of any Licensed Compounds in the Field; (iii) all claims of any 

  

 -4- 
 [***] Represents information redacted and filed separately with the Commission pursuant to a request for confidential treatment under Rule 406 of the Securities Act of 1933, as amended. 

 
foreign counterpart patent applications and/or issued patents of (i) and (ii) and (iv) any reissues, extensions, substitutions, confirmations,
registrations, revalidations, additions, continuations, continuations-in-part or divisions of or to any of the foregoing which are hereafter granted in the Territory. Exhibit A shall be updated periodically to reflect the current status of the
Patent Rights. 
 (m) “Phase l” means, with respect to human clinical trials, initial introduction of new drug in humans (patients
or normal volunteers, as appropriate). Controlled studies are designed to determine metabolism, pharmacologic actions, side effects associated with single and increasing multiple-doses, and, if possible, to gain early evidence of efficacy.

 (n) “Phase II” means, with respect to human clinical trials, controlled clinical studies designed to evaluate the effectiveness
of a drug for a particular indication (or indications) in patients with the disease or condition under study and to determine the short-term side effects and risks associated with the drug. 
 (o) “Phase III” means, with respect to human clinical trials, expanded controlled studies performed after preliminary evidence suggests
effectiveness of a drug has been obtained. These studies are intended to gather additional information about effectiveness and safety needed to evaluate overall benefit/risk relationship of the drug and to provide the basis for physician labelling.

  

 -5- 

 (p) “Territory” means every country in the world. 
 (q) “Trademark” means any trademark selected and registered by SCHERING in the Territory for the marketing of Licensed Products. 
 (r) “Valid Claim” means any claim contained in any pending patent application or issued patent included within the Patent Rights which has not
been abandoned or declared invalid in a non-appealable order and which would be infringed by the manufacture or sale of Licensed Products in the absence of the licenses granted in this Agreement. 
 ARTICLE 2 – LICENSE GRANT 
 ENDORECHERCHE hereby grants to SCHERING, and SCHERING hereby accepts from ENDORECHERCHE, exclusive, worldwide licenses under the Patent Rights and to use ENDORECHERCHE Know-How, with a right of sublicense, to make, have made, use and sell
Licensed Compounds and Licensed Products in the Field in the Territory. The foregoing licenses shall be exclusive, even as to ENDORECHERCHE, except as necessary for ENDORECHERCHE to make and use Licensed Compounds for the express purposes stated in
this Agreement. 
 ARTICLE 3 – PAYMENTS AND ROYALTIES 
 (a) In partial consideration of the grants of rights to SCHERING contained in this Agreement, and subject to the other terms in this Agreement, SCHERING
agrees to make the following payments in U.S. dollars to ENDORECHERCHE which shall be non-refundable and non-creditable against future royalties: 
 (i) $[***] upon the date this Agreement becomes effective; 
  

 -6- 

 (ii) $[***] upon completion of [***] and SCHERING’s notification to
ENDORECHERCHE of its decision to conduct or have conducted by ENDORECHERCHE [***] of such Licensed Compound; 
 (iii)
$[***] when [***] are completed. Completion for purposes of this Paragraph means receipt by SCHERING of [***]. 
 (iv) $[***] upon completion of [***]; 
 (v) $[***] upon [***]. Completion shall mean for
purposes of this Paragraph [***]. 
 (vi) $[***] upon the [***]. 
  

 -7- 
 [***] Represents information redacted and filed separately with the Commission pursuant to a request for confidential treatment under Rule 406 of the Securities Act of 1933, as amended. 

 (vii) $[***] upon the [***]. 
 (viii) $[***] upon [***] discovered by ENDORECHERCHE and developed by or at the request of SCHERING with [***] and
[***]. 
 Unless this Agreement is terminated pursuant to the operation of Paragraph (c) (i) of Article 7, amounts in sections (i)-
(ii) are guaranteed payments, provided ENDORECHERCHE has cured any material breach of the Agreement terms, as provided herein, prior to the due date{s) of such payments. And the payments in sections (iii)- (viii) will be paid upon
completion of the respective milestone to the extent this Agreement is still in effect on the due date. Each of the aforementioned payments will only be made once for a total aggregate sum of $13.5 million dollars, regardless of how many Licensed
Compounds or Licensed Products are discovered, developed and commercially marketed pursuant to the terms of this Agreement. The parties will mutually agree to, with respect to any Licensed Compound which SCHERING elects to clinically test in phase
III clinical trials under an IND, (a) a completion date for the phase III clinical 

  

 -8- 
 [***] Represents information redacted and filed separately with the Commission pursuant to a request for confidential treatment under Rule 406 of the Securities Act of 1933, as amended. 

 
trials for Licensed Compounds and (b) a submission date for the NDA. The timetables will be predicated on timetables SCHERING establishes for its own
drugs of similar status. In the event that SCHERING is delayed more than one (1) year from meeting the date established for (a) above for reasons within its control, provided ENDORECHERCHE has not caused or materially contributed to the
delay, SCHERING shall then be obligated to promptly make the payment specified in Paragraph (v) of this Article. In the event SCHERING is delayed more than one (1) year from meeting the date established for (b) above for reasons
within its control, provided ENDORECHERCHE has not caused or materially contributed to the delay, SCHERING shall then be obligated to promptly make the payment specified in Paragraph (iv) of this Article. 
 (b) On the last business day of May, August, November and February in each and every calendar year during the term of this Agreement, commencing upon
first marketing of Licensed Products hereunder, SCHERING shall furnish and deliver to ENDORECHERCHE a full and true accounting of its Net Sales of Licensed products hereunder during the three (3) month period ending with the previous
March 31st, June 30th, September 30th and December 31st and shall simultaneously pay to ENDORECHERCHE a sum equal to the aggregate of the Earned Royalty due thereon. 
 (c) Any Affiliate of SCHERING may pay directly to ENDORECHERCHE Earned Royalty due on such Affiliate’s Net Sales hereunder. Whenever SCHERING shall
reasonably demonstrate to ENDORECHERCHE that, in order to facilitate direct royalty 

  

 -9- 

 
payments by an Affiliate, it is desirable that a separate license agreement be entered into between ENDORECHERCHE and such Affiliate. ENDORECHERCHE will
grant such license directly to such Affiliate by means of an agreement which shall be consistent with the provisions hereof. 
 (d) Earned
Royalty shall be payable from the country in which earned in local currency and subject to foreign exchange regulations then prevailing. Earned Royalty payments shall be made in United States dollars to the extent that free conversion to United
States dollars is permitted. The rate of exchange to be used in any such conversion from the currency in the country where such Net Sales are made shall be the commercial rate of exchange prevailing in the United States on the last day of the
calendar quarter for which such payments are made as customarily quoted. If, due to restrictions or prohibitions imposed by national or international authority, payments cannot be made as aforesaid, the parties shall consult with a view to finding a
prompt and acceptable solution, and SCHERING will from time to time, deal with such monies as ENDORECHERCHE may lawfully direct at no additional out-of-pocket expense. Notwithstanding the foregoing, if Earned Royalties in any country cannot be
remitted to ENDORECHERCHE for any reason within six (6) months after the end of the calendar quarter during which they are earned, then SCHERING shall be obligated to deposit the Earned Royalties in a bank account in such country in the name of
ENDORECHERCHE. 
  

 -10- 

 (e) No Earned Royalty shall be payable in respect of sales between and among SCHERING, its Affiliates and
sublicensees, it being understood that royalties are to be paid on resale in the form of Licensed Products to independent third parties. 
 (f) If SCHERING shall hereafter be required, in respect of its sale of Licensed Products, to pay royalties to any third party whose patents may be infringed by such sales, SCHERING may deduct [***]%)of any Earned Royalty due
ENDORECHERCHE hereunder to reimburse it for any royalties payable to third parties. If SCHERING has knowledge of possible infringement of third party patent rights, SCHERING will advise ENDORECHERCHE as soon as possible and permit ENDORECHERCHE
consultation rights with respect to any proposed decision which SCHERING intends to take on the subject. SCHERING shall use diligent efforts, consistent with its reasonable business interests, to negotiate a settlement with a third party on
commercially reasonable terms. 
 (g) With respect to each Licensed Product in any country in the Territory for which Earned Royalties are
due hereunder, Earned Royalty shall be paid hereunder with respect to Net Sales for the longer period of twelve (12) years from the date of first commercial sale in such country of the Licensed product hereunder or for so long as any Valid
Claim is utilized in the manufacture or sale in such country in such country of such Licensed Product hereunder. Upon expiration of the obligation to pay Earned Royalty on Net Sales hereunder with respect to a Licensed Product in a country in the

  

 -11- 
 [***] Represents information redacted and filed separately with the Commission pursuant to a request for confidential treatment under Rule 406 of the Securities Act of 1933, as amended. 

 
Territory, SCHERING shall thereafter be free to use and commercialize at no cost any remaining proprietary rights granted pursuant to Article 2 herein as its
sees fit in such country. 
 (h) SCHERING shall maintain books of account and adequate records of all sales of Licensed Products.
ENDORECHERCHE shall have the right, by an independent public accountant reasonably acceptable to SCHERING, employed by it and at its own expense, to examine pertinent books and records of SCHERING at all reasonable times (but not more often than
once each calendar year) for the purpose of determining and reporting to ENDORECHERCHE the correctness of royalty payments made hereunder; it being understood that such examination with respect to any quarterly accounting period hereunder shall take
place not later than three (3) years following the expiration of said period. 
 (i) For phase II clinical studies and NDA toxicology
work performed by ENDORECHERCHE, in respect to Licensed Compounds designated by SCHERING, SCHERING shall reimburse ENDORECHERCHE for its properly documented actual out-of-pocket expenses for the conduct of such work. Invoices with supporting
documentation may be submitted [***] and will be payable [***]. ENDORECHERCHE will negotiate clinical grants and required laboratory work and toxicology studies at [***]. 
  

 -12- 
 [***] Represents information redacted and filed separately with the Commission pursuant to a request for confidential treatment under Rule 406 of the Securities Act of 1933, as amended. 

 ARTICLE 4 – DEVELOPMENT EFFORTS 
 (a) ENDORECHERCHE will continue its drug discovery efforts in the Field using its best efforts during the four (4) year period commencing on the
effective date of this Agreement and will continue its development efforts as necessary during the term of this Agreement using its best efforts to meet the milestones described in paragraph (a) of Article 3 (such discovery and development
efforts hereinafter referred to as the “Program”). In no event shall ENDORECHERCHE be obligated hereunder to undertake any new drug discovery efforts after the four (4) year term of the program or any extension thereof pursuant to the
operation of this Paragraph (a). The program shall include, without limitation, ENDORECHERCHE’s efforts directed toward the development of antiestrogen and antiandrogen compounds useful in the treatment of cancer. ENDORECHERCHE’s
activities will include, without limitation, (i) compound synthesis, (ii) pharmacology, mechanism of actions and absorption, distribution, metabolism and excretion studies, (iii) manufacture of clinical and toxicology materials for
pre- clinical, Phase l and Phase II clinical trials under an IND, (iv) conduct of preclinical studies, (v) conduct of sufficient toxicology work necessary for IND filings, (vi) conduct of Phase l clinical studies under an IND,
(vii) conduct of phase II clinical trials under an IND for clinical indications specified by SCHERING and (viii) toxicology studies required for NDA approval. SCHERING will have the right to review and approve in 

  

 -13- 

 
advance all toxicology and clinical protocols. In support of the program, and subject to the other terms and conditions of this Agreement, SCHERING will
either conduct or pay for Phase III clinical studies and will submit NDA and foreign health registration applications. SCHERING shall have the option, but not the obligation, to extend the aforementioned four (4) year drug discovery period for
up to two (2) additional one (1) year periods, or a total of six (6) years, upon giving at least ninety (90) days notice prior to the end of the fourth year after the effective date with respect to the fifth year and ninety
(90) days notice prior to the end of the fifth year with respect to the sixth year. In further partial consideration of the grants of rights to SCHERING contained in this Agreement, and subject to the other terms in this Agreement, SCHERING
will pay to the extent this Agreement is still in effect on the due date(s), an additional $3,000,000 to ENDORECHERCHE promptly after the commencement of each applicable renewal year. ENDORECHERCHE acknowledges that SCHERING’s renewal or
failure to renew the aforementioned four (4) year period shall have no effect on ENDORECHERCHE’s continuing obligation to meet the milestones described in Paragraph (a) of Article 3 of this Agreement. During the duration of the
program, as it may be extended, while this Agreement remains in effect, neither ENDORECHERCHE nor Dr. Fernand Labrie will participate in, alone or with others, any other research and/or development of antiestrogen and/or antiandrogen compounds
for the prophylactic or therapeutic treatment of cancer in animals or man. 
  

 -14- 
 [***] Represents information redacted and filed separately with the Commission pursuant to a request for confidential treatment under Rule 406 of the Securities Act of 1933, as amended. 

 (b) Promptly after the effective date of this Agreement, ENDORECHERCHE shall disclose all of its existing
Know-How to SCHERING. During the term of this Agreement, ENDORECHERCHE shall make available to SCHERING, in a timely fashion, all additional ENDORECHERCHE Know-How developed which is necessary or useful to SCHERING’s evaluation of Licensed
Compounds and development and registration for marketing approval in the Territory of Licensed Compounds and Licensed Products. 
 (c) At
least [***] during the period described in Paragraph (a) of this Article, ENDORECHERCHE shall provide written reports of its development activities and results in the program in a form reasonably specified by SCHERING. 
 (d) At any time during the term of this Agreement, ENDORECHERCHE shall permit representatives of SCHERING to visit ENDORECHERCHE’s premises and view
program work in progress. ENDORECHERCHE shall also permit SCHERING to review any data or documentation (and make copies), arising out of or relating to the program, including clinical trial and toxicology data, but without any patient identifying
information. ENDORECHERCHE shall not be required to maintain such records and data beyond the period required by applicable laws and regulations, but shall endeavor to offer to provide original copies of such records to SCHERING prior to their
destruction. 
  

 -15- 
 [***] Represents information redacted and filed separately with the Commission pursuant to a request for confidential treatment under Rule 406 of the Securities Act of 1933, as amended. 

 (e) During the term of this Agreement, at the request of ENDORECHERCHE, SCHERING will provide summaries
to ENDORECHERCHE of the results of its evaluation of Licensed Compounds and the results of clinical testing and related in vitro and in vivo testing. SCHERING will also comply with the reasonable requests of ENDORECHERCHE to review any data or
documentation (and make copies) describing the results of its evaluation of Licensed Compounds and all results including clinical testing and related in vitro and in vivo testing. 
 (f) ENDORECHERCHE shall diligently continue pre-clinical and clinical testing through the completion of Phase l and Phase II clinical trials and NDA
toxicology work under IND(s) for Licensed Compounds mutually agreed upon by SCHERING and ENDORECHERCHE from time-to-time during the period set forth in Paragraph (a) of this Article. All preclinical, clinical and toxicology work undertaken by
ENDORECHERCHE hereunder shall be conducted in compliance with all applicable laws and regulations. SCHERING agrees to diligently reach a decision in connection with the development of a Licensed product hereunder whenever such a decision is required
at any stage of the Program. At the conclusion of any Phase l or Phase II clinical trials for any Licensed Compound, at the request of SCHERING, ENDORECHERCHE shall promptly transfer the IND to SCHERING or at the option of SCHERING shall permit
SCHERING to reference the IND if SCHERING files a separate IND. 
  

 -16- 

 (g) For any Licensed Products marketed by SCHERING in the Territory, SCHERING agrees to use diligent
efforts to market which are comparable to efforts it uses with other of its products of like status. 
 (h) ENDORECHERCHE shall pay all costs
of the program with respect to the first Licensed Compound through Phase l clinicals under an IND, including, without limitation, toxicology work needed to support IND(S), clinical supplies of Licensed Compounds, etc. ENDORECHERCHE will conduct
Phase II clinical trials and NDA toxicology for Licensed Compound on the terms set forth in this Agreement, including those contained in Paragraph (i) of Article 3 and, if requested, Phase III clinical trials on commercially reasonable terms to
be negotiated. 
 (i) For the second or any subsequent Licensed Compound designated by SCHERING for development, SCHERING shall at its option
either reimburse ENDORECHERCHE, [***] for for all development work through phase l clinicals, [***] or perform such work itself. 
 (j) Except for the proper exercise of any licenses granted and rights reserved under the provisions of this Agreement, each party agrees that it and its Affiliates (and sublicensees in the case of SCHERING) will not publish or otherwise
divulge or use for its or their own benefit confidential information furnished to it by the other, and in addition in the case of ENDORECHERCHE Program results, without the prior written approval of such other 

  

 -17- 
 [***] Represents information redacted and filed separately with the Commission pursuant to a request for confidential treatment under Rule 406 of the Securities Act of 1933, as amended. 

 
party in each instance. The foregoing obligation shall not be imposed on a party with respect to any information which it can demonstrate (i) was at the
time of disclosure to it (or shall thereafter, but prior to its publication, divulgence or use for the benefit of a party or any of its Affiliates, become, through no fault of such party or its Affiliates) a part of the public domain by publication
or otherwise; or (ii) was already properly and lawfully in its possession at the time it was received from the other party; or (iii) was lawfully received from a third party who was under no obligation of confidentiality to the disclosing
party with respect thereto; or (iv) is required by law to be disclosed (but only to the extent of such required disclosure). This obligation shall extend until the last to occur of (i) the expiration of this Agreement, or
(ii) [***] years following the date of this Agreement, or (iii) [***] years following any termination of this Agreement prior to expiration thereof. 
 ARTICLE 5 – TRADEMARKS 
 SCHERING shall be free to use and to register in
any trademark office in the Territory any Trademark for use with Licensed products it desires in its sole discretion. SCHERING shall own all right, title and interest in and to the Trademark in its own name or that of its designated Affiliate during
and after the term of this Agreement. 
  

 -18- 
 [***] Represents information redacted and filed separately with the Commission pursuant to a request for confidential treatment under Rule 406 of the Securities Act of 1933, as amended. 

 ARTICLE 6 – PATENT RIGHTS AND UNLICENSED SALES 
 As long as SCHERING has rights to Licensed Compounds hereunder, ENDORECHERCHE shall, or shall permit SCHERING, as hereinafter provided to, prepare, file
and prosecute, if feasible, and maintain issued patents with respect to such patentable Licensed Compounds which remain potential candidates for development and marketing hereunder, for any compositions of matter, methods of use thereof or processes
therefore in accordance with the terms of this Article, as follows: 
 (a) After the effective date of this Agreement if SCHERING wishes
patent protection in any country or countries in the Territory, ENDORECHERCHE shall obtain and maintain such patents and SCHERING shall reimburse ENDORECHERCHE for [***] related thereto. [***] received by ENDORECHERCHE to reimburse it
for patent expenses shall not be counted as an off-set against [***] for purposes of the aforementioned calculation. SCHERING shall be provided reasonable opportunity to participate in the selection of patent counsel and review and comment
upon the contents of any proposed patent application and on the contents of any document relating to the prosecution and maintenance of issued patents thereof and at its option, in lieu of the foregoing, SCHERING may prepare and prosecute any patent
application(s) and maintain any issued patent(s) itself solely at its expense. For patents prosecuted and maintained by ENDORECHERCHE, SCHERING shall reimburse 

  

 -19- 
 [***] Represents information redacted and filed separately with the Commission pursuant to a request for confidential treatment under Rule 406 of the Securities Act of 1933, as amended. 

 
ENDORECHERCHE [***] with respect to those issued patents claiming [***] and/or [***]. It is the intention of the parties that any patent
application, as filed and prosecuted, shall be of the same quality, scope and coverage as would be sought by the party filing for its own valuable proprietary property which it did not intend to license. 
 (b) With respect to any issued patent within the Patent Rights, ENDORECHERCHE will designate SCHERING as its agent, for obtaining an extension of such
patent where available in any country in the Territory or if not feasible, at SCHERING’s option, permit SCHERING to file in ENDORECHERCHE’s name, or diligently obtain such extension for SCHERING at SCHERING’s expense. Furthermore,
ENDORECHERCHE agrees to provide reasonable assistance, at no out-of-pocket expense, to facilitate SCHERING’s efforts to obtain any extension. 
 (c) ENDORECHERCHE agrees to promptly take all reasonable legal action necessary to protect the Patent Rights against infringements by third parties. If within three (3) months following receipt of written notice from SCHERING,
ENDORECHERCHE fails to take such action to halt the alleged infringement, SCHERING shall, in its sole discretion, have the right to take 

  

 -20- 
 [***] Represents information redacted and filed separately with the Commission pursuant to a request for confidential treatment under Rule 406 of the Securities Act of 1933, as amended. 

 
such action as it deems warranted in its own name or in the name of ENDORECHERCHE. ENDORECHERCHE agrees to render such reasonable assistance (which
assistance does not place unduly burdensome demands on ENDORECHERCHE’s time or finances) as SCHERING may request in the event such action is taken by SCHERING. Costs of maintaining any such action and damages recovered therefrom shall be paid
by and belong to the party bringing the action. If SCHERING consents in the exercise of its sole discretion to a license to any third party infringer hereunder, then after deduction by SCHERING of any costs and expenses of prosecuting any claims
against the third party prior to licensing such party which are incurred by SCHERING, the parties shall split any advance or running royalty payments received from any third party, [***]%) to SCHERING and [***]%) percent to
ENDORECHERCHE. 
 ARTICLE 7 – TERM AND TERMINATION 
 (a) Unless sooner cancelled or terminated under the provisions hereof, this Agreement shall expire thirty (30) years after its effective date. To the extent not previously granted, SCHERING shall thereafter be
free to use and commercialize at no cost any remaining proprietary rights granted pursuant to Article 2 herein as it sees fit in the Territory. 
 (b) Either party may, at its option, terminate this Agreement by giving to the other party prior notice in writing to that effect of not less than ninety (90) days in the event the 

  

 -21- 
 [***] Represents information redacted and filed separately with the Commission pursuant to a request for confidential treatment under Rule 406 of the Securities Act of 1933, as amended. 

 
other party shall commit a material breach of this Agreement, and shall fail to cure such breach during the ninety (90) day period following receipt of
said notice from the non-breaching party or such longer period as may be necessary, provided the breaching party continues its diligent efforts to cure; provided, however, that any such cancellation and termination shall not release the breaching
party from any obligations hereunder incurred prior thereto and provided further that if a breach by SCHERING occurs after the conclusion of the five (5) year period described in Article 4 or any extension thereto, the Agreement shall be
terminable by ENDORECHERCHE only with respect to Licensed Compound(s) or Licensed Product(s) to which the breach specifically relates. 
 (c)
SCHERING shall have the right to terminate this Agreement (i) for any reason upon at least ninety (90) days prior notice effective on the second year anniversary of the effective date of this Agreement or (ii) upon written notice
within ninety (90) days after the four (4) year term of the Program, or any extension thereof, if at the time of such notice no Licensed Compounds are being tested in Phase l, Phase II or Phase III clinical trials pursuant to the terms of
this Agreement. 
 (d) The parties may at any time terminate this Agreement in part or in its entirety by mutual written agreement.

 (e) ENDORECHERCHE may, at its option, terminate this Agreement without penalty to SCHERING if on the sixth yearly anniversary of the
effective date of this Agreement SCHERING has 

  

 -22- 

 
not submitted an NDA for approval of at least one (1) Licensed Product, unless SCHERING is then making and continues to make diligent efforts to obtain
the first NDA approval of a Licensed Product, unless ENDORECHERCHE has caused or materially contributed to SCHERING’s inability to file or diligently pursue the NDA submission. 
 (f) Upon any partial or complete Agreement cancellation or termination, all Earned Royalties due for Net Sales of Licensed Products to the effective date
of said cancellation or termination shall accrue and become due and payable on the sixtieth (60th) day thereafter. 
 (g) In the event
of the cancellation or termination of any license rights with respect to a Licensed product prior to the expiration of this Agreement, inventory of Licensed product may be sold after date of termination provided Earned Royalties are paid thereon.

 (h) In the event this Agreement is terminated by SCHERING pursuant to Paragraph (c) of this Article or by the parties pursuant to
Paragraph (d) of this Article, then ENDORECHERCHE shall have the following rights and obligations: 
 (i) At the written
request of ENDORECHERCHE given within ninety (90) days of the termination, SCHERING will transfer or cause to be transferred to ENDORECHERCHE or its designee, to the extent feasible and with any out-of-pocket expenses associated with the
transfers) paid by ENDORECHERCHE, any government health registration and 

  

 -23- 

 
pricing approvals of SCHERING and its Affiliates for any Licensed products (excluding Licensed Combinations) which contain as the sole active pharmaceutical
ingredient(s) Licensed Compounds, and shall also promptly provide or cause to be provided any of its or its Affiliates Know-How relating to such Licensed Products and/or relating to any additional SCHERING Know-How developed during the term of
Program. Notwithstanding the foregoing, to the extent SCHERING has proprietary Know-How relating to manufacturing processes of such Licensed Compounds and Licensed Products, it shall only be required to disclose such Know-How hereunder if the
parties mutually agree on commercial terms to reasonably reimburse SCHERING for the use of such Know-How. 
 (ii) At the
written request of ENDORECHERCHE given within ninety (90) days of the termination, SCHERING agrees to grant with respect to the Licensed Compounds and Licensed products described in (i) of this Paragraph an exclusive, paid-up worldwide
license, with right of sublicense, to make, have made, use and sell such Licensed Compounds and Licensed Products under any applicable SCHERING patents and Know-How for any diseases and/or conditions in man and/or animals. 
 (iii) ENDORECHERCHE and any designee or sublicensee shall indemnify and hold SCHERING, its Affiliates and their respective employees,
officers, directors shareholders and 

  

 -24- 

 
agents harmless, to the maximum extent permitted by law, from and against any claims, liability, loss, damages, costs, or expenses (including reasonable
attorney’s fees) which the indemnified party may incur, suffer or be required to pay resulting from or arising in connection with the use or sale any Licensed Products, Licensed Compounds, SCHERING patent rights or Know-How described in this
Paragraph. Furthermore, to the maximum extent permitted by law, SCHERING makes no warranties, express or implied, with respect to any rights, Licensed Compounds or Licensed products described in this Paragraph and shall not be liable to
ENDORECHERCHE or any third party with respect to the manufacture, use or sale of any Licensed Compounds or Licensed Products described in this Paragraph and 
 (iv) SCHERING will return to ENDORECHERCHE or dispose of any ENDORECHERCHE’s Know-How to the extent feasible, as requested by
ENDORECHERCHE, within a reasonable time after the termination. 
 ARTICLE 8 – WARRANTIES AND LIABILITY 
 (a) Each party represents and warrants to the other party that it has the legal power, authority and right to enter into this Agreement and to perform
all of its respective obligations set forth in the Agreement terms, including the Exhibits. 
  

 -25- 

 (b) Each party represents and warrants that as of the effective date of this Agreement it is not a party
to any agreement, arrangement or understanding with any third party which in any way conflicts with its ability to fulfill any of its obligations under the terms of this Agreement, including the Exhibits. 
 (c) ENDORECHERCHE represents and warrants that the program has been approved by the Quebec Government as fulfilling the requirements for the fiscal
advantages and research incentives and that the document attached as Exhibit Band incorporated herein constitutes such formal and legally binding approval of the Quebec Government and further represents and warrants that it will use its best efforts
to maintain the research tax credits available, as a result of such approval, during the period described in Paragraph (a) of Article 4. 
 (d) ENDORECHERCHE warrants that it has and shall retain all right, title and interest to the Patent Rights described in Paragraph (1) (i) of Article 1 and further warrants that is has and shall retain the right to obtain all
right, title and interest in all patentable inventions arising out of efforts by or on behalf of ENDORECHERCHE in the Program. 
 (e)
ENDORECHERCHE represents and warrants that it has entered into and will maintain a binding and enforceable agreement with Le Centre Hospitalier De L’Universite, Laval (hereinafter “CHUL”) under which ENDORECHERCHE has exclusive right
of assignment of all right, title and interest in any 

  

 -26- 

 
inventions, discoveries, research results and data, whether or not patentable, resulting from any work undertaken by CHUL during the term of the Program, as
it may be extended, relating to the discovery and development of antiestrogen and antiandrogen compounds useful in the treatment of cancer. 
 (f) Except as expressly provided in this Agreement, each party disclaims all warranties, express or implied, concerning or relating to Licensed Compounds and Licensed Products. 
 (g) Neither party shall be liable for incidental or consequential damages of the other party arising out of or resulting from a breach of this Agreement.

 ARTICLE 9 – MISCELLANEOUS 
 (a) The failure on the part of SCHERING or ENDORECHERCHE to exercise or enforce any right conferred upon it hereunder shall not be deemed to be a waiver of any such right, nor operate to bar the exercise or enforcement thereof at any time
or times thereafter. 
 (b) Any notice required or permitted to be given by the terms of this Agreement by a party shall be given by prepaid,
registered air mail, properly addressed to the address of the other party set forth below, or to such other address as may, from time to time, be designated in writing by such other party, and shall be deemed to have been given upon receipt:

  

			
	As To SCHERING:	  	SCHERING Corporation
		  	2000 Galloping Hill Road
		  	Kenilworth, New Jersey, U.S.A. 07033
		  	Attn.:
		
	cc:	  	Legal Director, Research
		  	and Licensing
		  	Schering-Plough
		  	Corporation 2000
		  	Galloping Hill Road
		  	Kenilworth, New Jersey, U.S.A. 07033
		
	As To ENDORECHERCHE:	  	
		
	 Dr. Fernand Labrie M.D.
	  	
		  	29 La Promenade
		  	St. Foy
		  	Quebec, G1W2J5
		  	Canada
		
	cc:	  	Andre Morisset, Esq.
		  	Edifice Iberville Trois
		  	2960 boul. Laurier Suite 500 Sainte-Fos,
		  	Quebec GIV 451

  

 -27- 

 (c) This Agreement shall be construed and interpreted according to the laws of the State of New Jersey
U.S.A., except with respect to its conflict of law provisions. 
 (d) Any claim or dispute arising in connection with this Agreement, or the
alleged breach thereof, shall be submitted to arbitration in New York City under the rules of the American Arbitration Association, and any award or decision made in such arbitration shall be binding and final upon the parties hereto. 
 (e) The captions to the Articles of this Agreement are for convenience only, and shall not be deemed of any force or effect whatsoever in construing this
Agreement. 
 (f) The terms and provisions contained herein constitute the entire Agreement between the parties and shall supersede all
previous communications, representations, agreements or understandings, either oral or written, between the parties hereto with respect to the subject matter hereof. No agreement or understanding varying or extending the same will be binding 

  

 -28- 

 
upon either party hereto unless in writing, signed by duly authorized officers of the respective parties, and referencing this Agreement. 
 (g) This Agreement shall not be assignable by either party except by SCHERING to an Affiliate of SCHERING. 
 (h) ENDORECHERCHE shall promptly report to SCHERING the details of any significant patient adverse drug reactions or suspected adverse drug reactions
with respect to any Licensed Compounds during any clinical trials occurring or conducted by or on behalf of ENDORECHERCHE. 
 (i) The terms
of this Agreement which by their intent or meaning have validity beyond the term of this Agreement shall survive the termination or expiration of this Agreement. 
 (j) ENDORECHERCHE agrees not to publicize this Agreement nor to disclose the terms and conditions herein, except to the extent required by law, and then only on a confidential basis to the extent feasible, or except
as consented to in advance by SCHERING in writing. 
 IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be executed in
duplicate by their duly authorized officers as of the date first above written. 
  

									
	 ENDORECHERCHE, INC.
	 		 	SCHERING CORPORATION
					
	 By:
	 	 /s/ Fernand Labrie
	 		 	By:	 	 /s/ illegible

  

 -29- 

 EXHIBIT A OF AGREEMENT WITH SCHERING CORPORATION 
 AND ENDORECHERCHE. INC. 
  

	I.	D.S. Patent Applications: 

  

							
	Title	  	 Serial No.
	  	 Filing Date

				
	1) 	  	Therapeutic [***]	  	[***]	  	[***]
				
	2) 	  	[***] Compounds	  	[***]	  	[***]
				
	3) 	  	Combination Therapy for Treatment of [***]	  	[***]	  	[***]
				
	4) 	  	Inhibitors of [***] and Methods for Their Production and Use	  	[***]	  	[***]
				
	5) 	  	Estrogen [***] Derivatives for Use in the Inhibition of [***] Activity	  	[***]	  	[***]
				
	6) 	  	Method of Treatment of [***]-Related Diseases	  	[***]	  	[***]
				
	7) 	  	[***] for Use in the Inhibition of [***] Activity	  	[***]	  	[***]
				
	8) 	  	Combination Therapy for the Prophylaxis and/or Treatment of [***]	  	[***]	  	[***]

  

	II.	Corresponding Foreign Patent Applications: 

  

	 	1)	Corresponding foreign patent applications entitled “[***] For Use in the [***]” claiming priority of [***] of the above-listed U.S. Patent
Applications, Serial Nos. [***], filed [***],[***], filed [***],[***], filed [***], and [***], filed [***] have been filed in [***], and [***].  

 The serial numbers and filing dates for each of the eight (8) corresponding foreign patent applications are given below: 

 

					
	 Country
	  	 Serial No.
	  	 Filing Data

			
	[***]	  	[***]	  	[***]
			
	[***]	  	[***]	  	[***]
			
	[***]	  	[***]	  	[***]
			
	[***]	  	[***]	  	[***]
			
	[***]	  	[***]	  	[***]
			
	[***]	  	[***]	  	[***]
			
	[***]	  	[***]	  	[***]
			
	[***]	  	[***]	  	[***]

  

 [***] Represents information redacted and filed separately with the Commission pursuant to a request for
confidential treatment under Rule 406 of the Securities Act of 1933, as amended. 

	2)	Corresponding foreign applications entitled “Combination Therapy for Treatment of [***]” claiming priority of U.S. Patent Appln. [***] filed [***]
have been filed as a PCT application designating all PCT countries, as well as in each of the following non-PCT countries: [***] and [***].  

 The serial numbers and filing dates of the PCT and the corresponding seven (7) non-PCT applictions are listed below: 
  

					
	 Country
	  	 Serial No.
	  	Filing Data
	[***]*	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	No Filing Receipt Yet	  	Forwarded to Associate 3/2/90
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	No Filing Receipt Yet	  	Forwarded to Associate 3/2/90

 * The PCT application
filed in the [***] Patent Office designates all PCT countries including the [***], most of the [***] countries, the [***] and [***] countries. 
  

 -2- 
 [***] Represents information redacted and filed separately with the Commission pursuant to a request for confidential treatment under Rule 406 of the Securities Act of 1933, as amended.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00117-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00117-of-00352.parquet"}]]